First in Human (FIH) trial results of MUVON's regenerative therapy for the treatment of stress urinary incontinence are now officially published in the International Urogynecology Journal. Deana Mohr, CEO: “We are thrilled with peer-review publication of our first-in-human phase I clinical trial demonstrating that the implantation of autologous muscle precursor cells for the treatment of Stress Urinary Incontinence in women is safe and feasible.” John F Coelho, Medical
MUVON's team is very proud to be amongst the 12 finalists for the ZKB Pionierpreis in 2023! The recognition of the impact of our mission is highly appreciated and we are looking forward to the final pitching days in May. The Pionierpreis has been awarded by the ZKB and the TECHNOPARK® Zürich foundation for 20 years and is seen as a leading innovation award for Swiss startups. Link to the full list of nominees.
Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.
